Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InSite Vision (INSV) and Senju Pharmaceutical have entered into a collaboration and license agreement to develop and market InSite’s azithromycin ophthalmic solution using DuraSite including AzaSite 1% and AzaSite Xtra 2% ocular antibiotics in Japan.
Subscribe to our email newsletter
Under the deal, Senju has agreed to pay InSite an upfront license fee, additional development milestones fees, and a percentage royalty on net sales.
InSite Vision chief executive officer Timothy Ruane said the company is happy to enter this strategic partnership with one of the leading ophthalmic pharmaceutical companies in Japan.
"We look forward to the approval of these important ocular antibiotics for the benefit of the Japanese people," Ruane said.
Japan-based Senju Pharmaceutical develops, manufactures and commercializes a variety of products on a global basis, specializing in ophthalmic preparations.
InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its new DuraSite platform technologies.
According to the company, the DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs.
Currently, the DuraSite platform leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite (azithromycin ophthalmic solution) 1%, marketed in the US by Akorn Pharmaceuticals, and Besivance (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb, a subsidiary of Valeant Pharmaceuticals.